FindTrial
Sign In

Phase 1/2 study of KHK7580

A dose escalation, single and multiple dose, Phase 1/2 study of KHK7580 for secondary hyperparathyroidism in patients receiving hemodialysis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222208
Enrollment
Unknown
Registered
2013-09-02
Start date
2013-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism in patients receiving hemodialysis

Interventions

investigational material(s) Generic name etc : KHK7580 INN of investigational material : Therapeutic category code : 39- Other agents affecting metabolism Dosage and Administration for Investigationa

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Written informed consent - Stable chronic renal disease patients receiving hemodialysis 3 times weekly for at least 12 weeks prior to the screening - intact PTH value of 240 pg/mL or more at the screening

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety Number and types of adverse events, laboratory tests, vital signs, electrocardiogram and ophthalmologic examination—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026